
Supplementary Data

Table S1.

ITGB4-targeted immunotherapies with or without anti-PD-L1 did not significantly affect hematopoiesis. At the end of *in vivo* experiments, whole blood samples were collected using tubes with K2EDTA and analyzed by the In-Vivo Animal Core of University of Michigan. Hematologic analysis indicated no significant reduction of blood components Hb and PLT in animals treated with PBS, mITGB4-DC, anti-PD-L1, mITGB4-DC + anti-PD-L1, TDLN T-mITGB4 BiAb or TDLN T-mITGB4 BiAb + anti-PD-L1. Data are shown as the average levels of Hb and PLT in each group (n=5).

Table S1

	Normal range	PBS	mITGB4-DC	Anti-PDL1	mITGB4-DC +Anti-PDL1	TDLN T-mITGB4 BiAb	TDLN T-mITGB4 BiAb +Anti-PDL1
Hb (g/dL)	11.0-15.1	Normal (12)	Normal (12.4)	Normal (12.9)	Normal (12.4)	Normal (12.6)	Normal (12.6)
PLT (K/uL)	592.-2972.	Normal (734)	Normal (900)	Normal (877)	Normal (708)	Normal (1014)	Normal (718)